0 17

Cited 64 times in

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

Authors
 Kim N. Chi  ;  Neeraj Agarwal  ;  Anders Bjartell  ;  Byung Ha Chung  ;  Andrea J. Pereira de Santana Gomes  ;  Robert Given  ;  Álvaro Juárez Soto  ;  Axel S. Merseburger  ;  Mustafa Özgüroğlu  ;  Hirotsugu Uemura  ;  Dingwei Ye  ;  Kris Deprince  ;  Vahid Naini  ;  Jinhui Li  ;  Shinta Cheng  ;  Margaret K. Yu  ;  Ke Zhang  ;  Julie S. Larsen  ;  Sharon McCarthy  ;  Simon Chowdhury  ;  the TITAN Investigators 
Citation
 NEW ENGLAND JOURNAL OF MEDICINE, Vol.381(1) : 13-24, 2019 
Journal Title
 NEW ENGLAND JOURNAL OF MEDICINE 
ISSN
 0028-4793 
Issue Date
2019
MeSH
Adenocarcinoma/drug therapy* ; Adenocarcinoma/mortality ; Adenocarcinoma/pathology ; Adenocarcinoma/secondary ; Adult ; Aged ; Aged, 80 and over ; Androgen Antagonists/adverse effects ; Androgen Antagonists/therapeutic use* ; Androgen Receptor Antagonists/adverse effects ; Androgen Receptor Antagonists/therapeutic use* ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Double-Blind Method ; Exanthema/chemically induced ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoplasm Grading ; Progression-Free Survival ; Prostatic Neoplasms/drug therapy* ; Prostatic Neoplasms/mortality ; Prostatic Neoplasms/pathology ; Quality of Life ; Radiography ; Thiohydantoins/adverse effects ; Thiohydantoins/therapeutic use*
Abstract
BACKGROUND: Apalutamide is an inhibitor of the ligand-binding domain of the androgen receptor. Whether the addition of apalutamide to androgen-deprivation therapy (ADT) would prolong radiographic progression-free survival and overall survival as compared with placebo plus ADT among patients with metastatic, castration-sensitive prostate cancer has not been determined. METHODS: In this double-blind, phase 3 trial, we randomly assigned patients with metastatic, castration-sensitive prostate cancer to receive apalutamide (240 mg per day) or placebo, added to ADT. Previous treatment for localized disease and previous docetaxel therapy were allowed. The primary end points were radiographic progression-free survival and overall survival. RESULTS: A total of 525 patients were assigned to receive apalutamide plus ADT and 527 to receive placebo plus ADT. The median age was 68 years. A total of 16.4% of the patients had undergone prostatectomy or received radiotherapy for localized disease, and 10.7% had received previous docetaxel therapy; 62.7% had high-volume disease, and 37.3% had low-volume disease. At the first interim analysis, with a median of 22.7 months of follow-up, the percentage of patients with radiographic progression-free survival at 24 months was 68.2% in the apalutamide group and 47.5% in the placebo group (hazard ratio for radiographic progression or death, 0.48; 95% confidence interval [CI], 0.39 to 0.60; P<0.001). Overall survival at 24 months was also greater with apalutamide than with placebo (82.4% in the apalutamide group vs. 73.5% in the placebo group; hazard ratio for death, 0.67; 95% CI, 0.51 to 0.89; P = 0.005). The frequency of grade 3 or 4 adverse events was 42.2% in the apalutamide group and 40.8% in the placebo group; rash was more common in the apalutamide group. CONCLUSIONS: In this trial involving patients with metastatic, castration-sensitive prostate cancer, overall survival and radiographic progression-free survival were significantly longer with the addition of apalutamide to ADT than with placebo plus ADT, and the side-effect profile did not differ substantially between the two groups. (Funded by Janssen Research and Development; TITAN ClinicalTrials.gov number, NCT02489318.).
Full Text
https://www.nejm.org/doi/full/10.1056/NEJMoa1903307
DOI
10.1056/NEJMoa1903307
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers
Yonsei Authors
Chung, Byung Ha(정병하) ORCID logo https://orcid.org/0000-0001-9817-3660
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/174553
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse